четверг, 30 июля 2015 г.

First accelerator of nanobiomedicine projects launches

Contributed by: VDI/VDE-IT

The EU-funded consortium ENATRANS (Enabling Nanomedicine TRANSlation) launches the first Translation Advisory Board (TAB), a new instrument to provide free of charge advice and support to ambitious international nanobiomedicine projects.
The call is open to companies, academics and private researchers in Europe promoting nanobiomedicine projects. A pool of technology and innovation champions as experts will serve the TAB to deliver concrete and invaluable advice to drive selected nanobiomedicine projects into innovative products for healthcare. Among projects, the most promising will benefit from further high value services such as in-depth advice, showcase and coaching. (Flyer available at http://www.enatrans.eu/public/services/translation-advisory-board/tab-flyer).

The applicants must have very promising nanobiomedicine projects, targeting unmet medical needs for patients.

Do you have an ambitious nanobiomedicine project?
Apply and benefit from high level advice and support: http://www.enatrans.eu/public/services/translation-advisory-board

Applications received till September 14, 2015 may be eligible for the first TAB-in session, which will gather selected projects in a first phase of the service to be organised in Dublin, 14 October, 2015.

Who are the experts?
Paul Smit - former senior position at Philips Healthcare, Mike Eaton - former senior positions at Celltech & UCB, David Bott - former senior position at BP, Ruediger Iden - former senior position at BASF, Eckhard Schwenner - former position at Bayer, Eric Mayer - CEO at Endomag, Laurent Levy - CEO at Nanobiotix

About the ENATRANS project
Enabling NAnomedicine TRANSlation, a Coordination and Support Action funded by the European Commission, has been built to help the translation of innovative projects related to nanobiomedicine to successfully go through the different stages of development from the idea to the patients and also improve global knowledge on nanobiomedicine. ENATRANS is led by a consortium of 7 partners belonging to the European Technology Platform for Nanomedicine (ETPN): CEA-LETI (Grenoble, France), Nanobiotix SA (Paris, France), Gesellschaft fur Bioanalytik Muenster e.V. (Muenster, Germany), Tel-Aviv University (Tel-Aviv, Israel), Fondazione Don Carlo Gnocchi ONLUS (Milan, Italy), TecMinho (Braga, Portugal) and VDI/VDE-IT (Berlin, Germany).

About ETPN
Created in 2005, the European Technology Platform for Nanomedicine is an initiative led by Industry and set up together with the European Commission to address the applications of nanotechnology to achieve breakthroughs in healthcare. The ETPN is structuring and federating the European Nanomedicine community and leading the communication toward the European Commission and the European Members States.